192 related articles for article (PubMed ID: 36859296)
1. Enzyme-catalyzed synthesis of selenium-doped manganese phosphate for synergistic therapy of drug-resistant colorectal cancer.
Pei M; Liu K; Qu X; Wang K; Chen Q; Zhang Y; Wang X; Wang Z; Li X; Chen F; Qin H; Zhang Y
J Nanobiotechnology; 2023 Mar; 21(1):72. PubMed ID: 36859296
[TBL] [Abstract][Full Text] [Related]
2. Selenium-doped calcium phosphate biomineral reverses multidrug resistance to enhance bone tumor chemotherapy.
Hu J; Jiang Y; Tan S; Zhu K; Cai T; Zhan T; He S; Chen F; Zhang C
Nanomedicine; 2021 Feb; 32():102322. PubMed ID: 33186694
[TBL] [Abstract][Full Text] [Related]
3. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways.
Pi J; Jiang J; Cai H; Yang F; Jin H; Yang P; Cai J; Chen ZW
Drug Deliv; 2017 Nov; 24(1):1549-1564. PubMed ID: 29019267
[TBL] [Abstract][Full Text] [Related]
4. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
5. Indocyanine green/doxorubicin-encapsulated functionalized nanoparticles for effective combination therapy against human MDR breast cancer.
Chen HH; Lu IL; Liu TI; Tsai YC; Chiang WH; Lin SC; Chiu HC
Colloids Surf B Biointerfaces; 2019 May; 177():294-305. PubMed ID: 30771581
[TBL] [Abstract][Full Text] [Related]
6. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
7. Se/Ru-Decorated Porous Metal-Organic Framework Nanoparticles for The Delivery of Pooled siRNAs to Reversing Multidrug Resistance in Taxol-Resistant Breast Cancer Cells.
Chen Q; Xu M; Zheng W; Xu T; Deng H; Liu J
ACS Appl Mater Interfaces; 2017 Mar; 9(8):6712-6724. PubMed ID: 28191840
[TBL] [Abstract][Full Text] [Related]
8. Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer.
Yuan ZT; Shi XJ; Yuan YX; Qiu YY; Zou Y; Liu C; Yu H; He X; Xu K; Yin PH
Oncotarget; 2017 Jul; 8(29):48012-48026. PubMed ID: 28624793
[TBL] [Abstract][Full Text] [Related]
9. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
[TBL] [Abstract][Full Text] [Related]
10. Silencing KLK12 expression via RGDfC-decorated selenium nanoparticles for the treatment of colorectal cancer in vitro and in vivo.
Xia Y; Tang G; Guo M; Xu T; Chen H; Lin Z; Li Y; Chen Y; Zhu B; Liu H; Cao J
Mater Sci Eng C Mater Biol Appl; 2020 May; 110():110594. PubMed ID: 32204058
[TBL] [Abstract][Full Text] [Related]
11. A pH-responsive platform combining chemodynamic therapy with limotherapy for simultaneous bioimaging and synergistic cancer therapy.
Xiao J; Zhang G; Xu R; Chen H; Wang H; Tian G; Wang B; Yang C; Bai G; Zhang Z; Yang H; Zhong K; Zou D; Wu Z
Biomaterials; 2019 Sep; 216():119254. PubMed ID: 31195303
[TBL] [Abstract][Full Text] [Related]
12. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo.
Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N
Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708
[TBL] [Abstract][Full Text] [Related]
13. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
15. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
16. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional polyamidoamine-modified selenium nanoparticles dual-delivering siRNA and cisplatin to A549/DDP cells for reversal multidrug resistance.
Zheng W; Cao C; Liu Y; Yu Q; Zheng C; Sun D; Ren X; Liu J
Acta Biomater; 2015 Jan; 11():368-80. PubMed ID: 25204523
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
19. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
[TBL] [Abstract][Full Text] [Related]
20. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
